Novel Therapeutic Options in Patients with Type 2 Diabetes and high cardiovascular Risk

被引：0
|
作者：
Laubner, Katharina [1 ]
Seufert, Jochen [2 ]
机构：
[1] Univ Freiburg Klinikum, Klin Innere Med 2, Abt Endokrinol & Diabetol, Freiburg, Germany
[2] Univ Freiburg Klinikum, Klin Innere Med 2, Endokrinol & Diabetol, Freiburg, Germany
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2016年 / 141卷 / 11期
关键词：
MELLITUS;
D O I：
10.1055/s-0042-107747
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SGLT2 inhibitors represent a novel therapeutic approach for the tretment of type 2 diabetes mellitus. Beyond glucose control, these drugs also induce weight loss and blod pressure reduction. In a specific cardiovascular outcome trial (EMPA-REG-OUTCOME), the SGLT 2 inhibitor empagliflozin has for the first time demonstrated to reduce cardiovascular and overall mortality as well as hospitalization for heart failure in patients with type 2 diabetes and high cardiovascular risk. These results will drastically affect future recommendations for the treatment of type 2 diabetes mellitus.). © Georg Thieme Verlag KG ·Stuttgart · New York.
引用
收藏
页码：757 / 760
页数：4
相关论文
共 50 条
  • [31] Targeting cardiovascular risk factors in patients with type 2 diabetes
    Holt, R
    DIABETES OBESITY & METABOLISM, 2003, 5 (04): : 269 - 269
  • [32] Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes
    Erdmann, E
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 107 (02) : 147 - 153
  • [33] Cardiovascular disease risk in patients with type 2 diabetes and hypertension
    Kawada, Tomoyuki
    JOURNAL OF HYPERTENSION, 2023, 41 (02)
  • [34] Bone markers and cardiovascular risk in type 2 diabetes patients
    Zwakenberg, Sabine R.
    van der Schouw, Yvonne T.
    Schalkwijk, Casper G.
    Spijkerman, Annemieke M. W.
    Beulens, Joline W. J.
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [35] Pioglitazone reduces cardiovascular risk in patients with type 2 diabetes
    Bierwirth, R. A.
    Dietlein, M.
    Franzen, C.
    Gruenerbel, A.
    Hofmann, C.
    Merke, J.
    Luebben, G.
    Karagiannis, E.
    DIABETOLOGE, 2008, 4 (07): : 542 - 548
  • [36] Reducing cardiovascular risk in patients with type 2 diabetes mellitus
    Nicholls, Stephen J.
    Ryden, Lars
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 : S1 - S1
  • [37] Bone markers and cardiovascular risk in type 2 diabetes patients
    Sabine R. Zwakenberg
    Yvonne T. van der Schouw
    Casper G. Schalkwijk
    Annemieke M. W. Spijkerman
    Joline W. J. Beulens
    Cardiovascular Diabetology, 17
  • [38] Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes
    Goldberg, RB
    AMERICAN JOURNAL OF MANAGED CARE, 2000, 6 (13): : S682 - S691
  • [39] Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus
    Kadoglou, N. P. E.
    Iliadis, F.
    Angelopoulou, N.
    Perrea, D.
    Liapis, C. D.
    Alevizos, M.
    DIABETIC MEDICINE, 2008, 25 (03) : 333 - 340
  • [40] Prevalence of the metabolic syndrome and associated novel cardiovascular risk factors in patients with Type 2 diabetes
    Bianchi, C
    Penno, G
    Giovannitti, MG
    Pucci, L
    Pellegrini, G
    Caricato, E
    Bertolotto, A
    Corfini, M
    Del Prato, S
    Miccoli, R
    DIABETOLOGIA, 2004, 47 : A124 - A125
12345